Outlook Therapeutics (OTLK) Assets Average (2016 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Assets Average of $20.1 million for Q1 2026, up 11.22% year-over-year from $18.0 million in Q1 2025, and up 8.98% quarter-over-quarter from $18.4 million in Q4 2025.
Outlook Therapeutics (OTLK) Assets Average (2016 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Assets Average for 11 consecutive years, with $20.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 11.22% year-over-year to $20.1 million; the TTM figure through Mar 2026 stood at $20.1 million (up 11.22% YoY), while the FY2025 annual figure was $23.7 million, down 22.44% from the prior year.
- Assets Average grew to $20.1 million in Q1 2026 per OTLK's latest filing, from $18.4 million in the prior quarter.
- Across five years, Assets Average topped out at $73.2 million in Q1 2022 and bottomed at $18.0 million in Q1 2025.
- Historically, Assets Average has averaged $37.1 million across 5 years, with a median of $38.0 million in 2024.
- Annual changes were most pronounced in 2022 — Assets Average soared 153.97% — and 2025, when it tumbled 60.92%.
- Outlook Therapeutics' Assets Average stood at $45.6 million in 2022, then sank by 40.82% to $27.0 million in 2023, then fell by 15.11% to $22.9 million in 2024, then fell by 19.65% to $18.4 million in 2025, then grew by 8.98% to $20.1 million in 2026.
- Business Quant data shows OTLK's Assets Average at $20.1 million in Q1 2026, $18.4 million in Q4 2025, and $20.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 19.82 Bn |
| 10 | Outlook Therapeutics | 95.21 Mn | 83.97 Mn | -8,265.00 | 24.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.07 Mn |
| Dec 31, 2025 | 18.41 Mn |
| Sep 30, 2025 | 20.49 Mn |
| Jun 30, 2025 | 20.73 Mn |
| Mar 31, 2025 | 18.04 Mn |
| Dec 31, 2024 | 22.91 Mn |
| Sep 30, 2024 | 37.96 Mn |
| Jun 30, 2024 | 53.06 Mn |
| Mar 31, 2024 | 40.36 Mn |
| Dec 31, 2023 | 26.99 Mn |
| Sep 30, 2023 | 38.37 Mn |
| Jun 30, 2023 | 49.24 Mn |
| Mar 31, 2023 | 58.36 Mn |
| Dec 31, 2022 | 45.61 Mn |
| Sep 30, 2022 | 33.56 Mn |
| Jun 30, 2022 | 53.14 Mn |
| Mar 31, 2022 | 73.18 Mn |
| Dec 31, 2021 | 50.74 Mn |
| Sep 30, 2021 | 27.85 Mn |
| Jun 30, 2021 | 39.00 Mn |